The results of Vepesid therapy in the treatment of malignant lymphomas.
Twenty-three patients with Hodgkin's disease and non-Hodgkin's lymphomas were treated by Vepesid. The dose of the drug was 150 mg/m2 daily for 5 consecutive days. This schedule was repeated every 3 weeks. The percentage and response were estimated according to WHO scale. There were complete responses and 6 partial responses lasting 13.7 and 5 months, respectively, on the average. The results of Vepesid therapy depended on the efficiency of previous treatment.
Pawlicki
M
M
M. Skłodowska-Curie Institute of Oncology, Department of Medical Oncology, Cracow, Poland.
Sliz
E
E
Rachtan
J
J
D000328:Adult; D000368:Aged; D005047:Etoposide / Q000009:adverse effects / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008223:Lymphoma / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged
D005047:Etoposide